TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03515421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frazier 3 Verio
Description: In vitro diagnostic device (IVDD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frazier 3 UltraPlus
Description: In vitro diagnostic device (IVDD)
Study: NCT00757068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT addressing postpartum mood and weight concerns
Description: Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Behavioral Therapy
Description: Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
Study: NCT02560649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Entecavir
Description: Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Entecavir
Description: Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
Study: NCT01178840

Intervention type: DEVICE
Group type: OTHER
Intervention: WC then FC2
Description: 4 uses of WC followed by 4 uses of FC2

Intervention type: DEVICE
Group type: OTHER
Intervention: FC2 then WC
Description: 4 uses of WC followed by 4 uses of FC2
Study: NCT04347421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil group
Description: This group takes 500 mg/day Krill oil for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group takes 500 mg/day Placebo for 12 weeks.
Study: NCT03004885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrismaLung
Description: Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrismaLung
Description: Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
Study: NCT02560649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Lamivudine
Description: Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Lamivudine
Description: Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Adefovir
Description: Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
Study: NCT03004885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PrismaLung
Description: Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
Study: NCT01078948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Delivery of mild current to specified brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Delivery of mild current to specified brain regions.
Study: NCT02295462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centered Care
Description: Medication Review + Person-centered Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised Treatment
Description: Medication Review only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised Treatment
Description: Medication Review only
Study: NCT02560649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Adefovir
Description: Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus Tenofovir
Description: Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a plus Tenofovir
Description: Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5mg qd for 24 weeks(Arm C)
Study: NCT03667105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MC
Description: Xenogenous graft placed in the surgical site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XDM
Description: Xenogenous dermal collagen graft placed in the surgical site.
Study: NCT02560649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 0.1g qd for 24 weeks(Arm C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir 10mg qd for 24 weeks(ArmC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Tenofovir 300mg qd for 24 weeks(Arm C)
Study: NCT01426269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning

Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Study: NCT00596609

Intervention type: DRUG
Intervention: Intrathecal Morphine
Description: * In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection.
Study: NCT00492271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Friulimicin B
Description: Intravenous, once daily, single dose
Study: NCT03426033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 25mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 25mg tablet administered orally
Study: NCT03731377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
Study: NCT01763086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
Study: NCT02759588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Description: GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
Study: NCT00414544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CosmetaLife
Description: Dermal filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Dermal filler
Study: NCT00549848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Description: See Detailed Description section for details of treatment interventions.
Study: NCT05346978

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nasturtium (Tropaeolum majus)
Description: Freeze dried nasturtium (Edible flower)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: collagen colored with green pigment used in the food industry
Study: NCT03381820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumental folk music
Description: The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
Study: NCT02504086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Support
Description: 3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
Study: NCT00404417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A / Placebo
Description: Botulinum Toxin A at first injection / Placebo at second injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A / Botulinum Toxin A
Description: Botulinum Toxin A at first injection / Botulinum Toxin A at second injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo / Botulinum Toxin A
Description: Placebo at first injection / Botulinum Toxin A at second injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Placebo
Description: Placebo at first injection / Placebo at second injection
Study: NCT01547546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: Multiple doses
Study: NCT01811706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally every 12 hours, for a 4 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally every 12 hours, for a 4 week period.
Study: NCT02830906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
Study: NCT02764944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple non-exposure EFTR
Description: This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
Study: NCT00701896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline tartrate
Description: 1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
Study: NCT03839914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin powder
Description: For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
Study: NCT04358406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human plasma gelsolin (Rhu-pGSN)
Description: Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
Study: NCT02156492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.
Study: NCT04388098

Intervention type: OTHER
Intervention: Diagnosis of caries experience and periodontal health

Intervention type: OTHER
Intervention: Diagnosis of caries experience and periodontal health
Study: NCT02675283

Intervention type: DEVICE
Group type: OTHER
Intervention: Simtomax
Description: Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
Study: NCT01319110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
Study: NCT00701896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine gum and nicotine patch

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Control
Description: No treatment intervention only information and procedures.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Control
Description: No treatment intervention only information and procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: 60 minute one-on-one Interview
Study: NCT03173053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Mouthwash or bodywash
Study: NCT01195883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
Study: NCT06556316

Intervention type: BEHAVIORAL
Intervention: Cognitive Intervention with the Categorization Program
Description: Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program

Intervention type: BEHAVIORAL
Intervention: Cognitive Intervention with the Categorization Program
Description: Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
Study: NCT04358406

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
Study: NCT00416741

Intervention type: BEHAVIORAL
Intervention: Implementation of guidelines
Description: Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose

Intervention type: BEHAVIORAL
Intervention: Implementation of guidelines
Description: Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
Study: NCT01195883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
Study: NCT03335748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training Cogmed program
Description: Cognitive training Cogmed program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training Cogmed program
Description: Cognitive training Cogmed program
Study: NCT01451411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan hydrochloride
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT03483389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl
Description: Randomized within-subjects design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol, Ethyl
Description: Randomized within-subjects design
Study: NCT01867216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922470
Description: Administered orally as capsules
Study: NCT02833506

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant NY-ESO-1 Protein
Description: Given recombinant NY-ESO-1 protein SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NY-ESO-1 Protein
Description: Given recombinant NY-ESO-1 protein SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT00994097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study: NCT03173053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Mouthwash or bodywash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Description: Nasal ointment
Study: NCT00994097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study: NCT01319110

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
Study: NCT03173053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Description: Nasal ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Shampoo
Study: NCT01766570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uncontrolled nutritional intervention with a supplemental beverage
Description: Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03173053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Shampoo